Literature DB >> 8904929

Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes.

P Di Bonito1, A De Bellis, B Capaldo, S Turco, G Corigliano, E Pace, A Bizzarro.   

Abstract

To evaluate the predictive factors of insulin requirement in newly diagnosed patients with unclassifiable diabetes, 54 consecutive patients, aged less than 35 years, were prospectively followed for 3 years or more. At entry, haemoglobin HbA1c, basal and stimulated C-peptide concentrations, HLA phenotype, islet cell antibodies (ICA) status, and serum levels of soluble CD8 antigen (sCD8) were evaluated. After a median time of 9 (range 2-32) months, 31 patients (group 1) required insulin therapy, whereas 23 patients (group 2) remained non-insulin-requiring after 36 months. Group 1 patients were younger (P < 0.05) and had higher HbA1c and sCD8 serum levels (P < 0.0001), respectively), a higher frequency of ICA positivity and of HLA DR3 and/or DR4 phenotype (P < 0.005 and P < 0.0001, respectively), and lower C-peptide concentrations (P < 0.005 and P < 0.0001, basal and stimulated, respectively) than group 2. The sensitivity, specificity, positive and negative predictive value, and overall accuracy for the subsequent insulin requirement were: sCD8 serum levels (> 737 U/ml), 100%, 65%, 79%, 100% and 85%, respectively; stimulated C-peptide (< 0.60 nmol/l), 71%, 96%, 96%, 74% and 81%, respectively; and ICA positivity (> 20 JDFU), 45%, 91%, 87%, 55% and 65%, respectively. Thus, higher sCD8 serum levels, low stimulated C-peptide concentrations and ICA positivity are the most powerful predictors of subsequent recourse to insulin therapy in young, newly detected patients with unclassifiable diabetes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904929     DOI: 10.1007/bf02048547

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  21 in total

1.  Soluble CD8 during T cell activation.

Authors:  B E Tomkinson; M C Brown; S H Ip; S Carrabis; J L Sullivan
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

2.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

3.  Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus.

Authors:  M Landin-Olsson; K O Nilsson; A Lernmark; G Sundkvist
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

4.  C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.

Authors:  O K Faber; C Binder
Journal:  Diabetes       Date:  1977-07       Impact factor: 9.461

5.  Genetic, immunologic, and environmental heterogeneity of IDDM. Incidence and 12-mo follow-up of an Italian population.

Authors:  G Pagano; P Cavallo-Perin; F Cavalot; A M Dall'Omo; P Masciola; R Suriani; A Amoroso; S E Curtoni; I Borelli; G Lenti
Journal:  Diabetes       Date:  1987-07       Impact factor: 9.461

6.  Immune abnormalities in diabetic patients not requiring insulin at diagnosis.

Authors:  U Di Mario; W J Irvine; D Q Borsey; J L Kyner; J Weston; C Galfo
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

7.  Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity.

Authors:  M R Christie; S Genovese; D Cassidy; E Bosi; T J Brown; M Lai; E Bonifacio; G F Bottazzo
Journal:  Diabetes       Date:  1994-10       Impact factor: 9.461

8.  Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes.

Authors:  P Santamaria; R E Nakhleh; D E Sutherland; J J Barbosa
Journal:  Diabetes       Date:  1992-01       Impact factor: 9.461

9.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.

Authors:  E Bonifacio; P J Bingley; M Shattock; B M Dean; D Dunger; E A Gale; G F Bottazzo
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

10.  Spontaneous release of the Leu-2 (T8) molecule from human T cells.

Authors:  J Fujimoto; S Levy; R Levy
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.